[Sense and sensibility: bipolar affective disorder as a battlefield of cognitions and emotions--lamotrigine therapy as a peacekeeper].
The cortico-limbic dysregulation theory of bipolar affective disorder (BAD) is supported by ample of recent research evidences. This concept is based on the dysharmonic regulation of prefrontal and anterior limbic structures manifested in a strong interaction of cognitive and affective symptoms. The major aim of the present review is to characterize the BAD specific cognitive profile and to describe the cognitive syndrome of BAD during the natural course of the disorder, based on recent findings in neurobiology, neuropathology, neuroradiology, cognitive psychology and neurogenetics. The authors recommend that BAD-associated cognitive symptoms should always be considered during the recognition, follow up and treatment phases of the disorder. The importance of the cognitive syndrome is also emphasized from the aspects of outcome and existing therapeutic regimens of the disorder. The cognitive syndrome-associated perspective of BAD could therefore provide new approaches regarding the long-term management issues of patients. Evidence from recent clinical trials is also summarized regarding the interactions of existing BAD treatment options with cognitive symptoms of the disorder, since all of the recommended antipsychotics and antiepileptics have a certain degree of cognitive toxicity. Based on the overview of the existing clinical trials, it was concluded that lamotrigine has the smallest cognitive toxicity among the mood stabilizers used for the treatment of BAD type-2. Therefore, as far as the cognitive toxicity profile is concerned, lamotrigine is recommended as the most promising therapeutic approach both for the treatment of bipolar depressive phases and relapse prevention. In addition, neuroprotective properties of the same molecule might also be beneficial regarding the proposed pathomechanism of BAD.
Kálmán
János
J
Szegedi Tudományegyetem, Pszichiátriai Klinika, Szeged.
Kálmán
János
J
D000293:Adolescent; D000328:Adult; D000339:Affect / Q000187:drug effects; D000368:Aged; D018692:Antimanic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology*; D002540:Cerebral Cortex / Q000187:drug effects; D002648:Child; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy* / Q000523:psychology; D044127:Epigenesis, Genetic; D006179:Gyrus Cinguli / Q000187:drug effects; D006801:Humans; D000077213:Lamotrigine; D008032:Limbic System / Q000187:drug effects; D018020:Lithium Compounds / Q000627:therapeutic use; D008875:Middle Aged; D012565:Schizophrenic Psychology; D013315:Stress, Psychological / Q000523:psychology; D016896:Treatment Outcome; D014227:Triazines / Q000494:pharmacology / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use
D018692:Antimanic Agents; D018020:Lithium Compounds; D014227:Triazines; D014635:Valproic Acid; D000077213:Lamotrigine